Merck KGaA cancer drug Stimuvax misses goal in Phase III trial
FRANKFURT Dec 19 (Reuters) - German drugmaker Merck KGaA said its cancer drug Stimuvax did not reach its target of improving survival of lung cancer patients in a late-stage study.
"Further analyses are planned in the coming weeks to explore the potential benefit-risk profile of L-BLP25 (Stimuvax) in certain populations," Merck said in a statement on Wednesday.
It said it would discuss this data with external experts and regulatory authorities over the coming months.
Stimuvax, a type of cancer vaccine, is being developed as a maintenance treatment for cancer patients treated with standard therapy of chemo and radiation. It is designed to help the patient's immune system fight certain cancer cells. (Reporting by Maria Sheahan)
- Exclusive: Secret contract tied NSA and security industry pioneer |
- U.S. aircraft hit by gunfire in South Sudan as conflict worsens
- With Fed out of the way, what's next on Wall Street?
- Analysis: Lost Brazil order raises threat to Boeing fighter jets
- Four men arrested in deadly N.J. shopping mall carjacking